中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.021 seconds)

    BLOOD TREATING MATERIAL
    2.
    发明专利
    BLOOD TREATING MATERIAL 未知

    公开(公告)号：CA1204667A

    公开(公告)日：1986-05-20

    申请号：CA438186

    申请日：1983-10-03

    Applicant: TORAY INDUSTRIES

    Inventor： KODAMA MASASHI ,  KATAYAMA YUTAKA ,  TANI TORU ,  TERAMOTO KAZUO ,  MURAKAMI MUTSUO

    IPC: A61K31/715 ,  A61K35/74 ,  A61K31/735

    Abstract: BLOOD TREATING AGENT The present invention provides (1) a blood-treating material containing a lipopolysaccharide derived from cell walls of Gram-negative bacteria and immobilized by an insoluble carrier containing an amino group and/or a carboxyl group, and (2) a process for producing the blood-treating material in which a condensing agent is reacted with a mixture of the lipopolysaccharide and the insoluble carrier. Lipopolysaccharides have been known to exhibit antitumor effects against malignant tumors. However, they have not been used safely, since their fatal doses are very close to the minimum effective doses in the treatment of such tumors. The present invention makes it possible to reduce the lethal toxicity of the abovementioned lipopolysaccharides and provide a therapy for cancer, because the unique bloodtreating material disclosed herein not only has antitumor effects similar to those of the lipopolysaccharides derived from the cell walls of Gram-negative bacteria but no fatal effects are observed at antitumor effective dosage levels.

    ENDOTOXIN NEUTRALIZER
    5.
    发明专利
    ENDOTOXIN NEUTRALIZER 失效

    公开(公告)号：JPH05329207A

    公开(公告)日：1993-12-14

    申请号：JP262593

    申请日：1993-01-11

    Applicant: TORAY INDUSTRIES

    Inventor： KODAMA MASATOMO ,  TANI TORU ,  HANAZAWA KAZUYOSHI ,  OKAFUJI TARO ,  TERAMOTO KAZUO ,  SAIKAI SHIRO

    IPC: A61K47/00 ,  A61K9/70 ,  A61K47/30 ,  A61M1/14 ,  A61M1/36 ,  B01D15/08 ,  B01J20/28 ,  B01J20/32

    Abstract: PURPOSE:To weaken a side effect while taking advantage of the endotoxin neutralizing effect of polymixin by immobilizing the polymixin on a fibrous carrier having the substituent selected from an alpha-acyl halide group, benzyl halide group and isocyanic acid group, thereby preparing the endotoxin neutralizer. CONSTITUTION:The endotoxin neutralizer is prepd. by immobilizing the polymixin to the fibrous carrier having the substituent selected from the alpha-acyl halide group, the benzyl halide group and the isocyanic acid group. The fibrous carrier is selected from polystyrene fibers or crosslinked polystyrene fibers, acrylic acid acrylonitride copolymer fibers and polyvinyl alcohol fibers having a carboxyl group. Since the endotoxin neutralizer is formed by immobilizing the polymixin at a high density, the neutralizer is capable of decomposing and nontoxicating the endotoxin in a soln. Since the polymixin does not elute into the soln., the soln. treated with the neutralizer does not exhibit toxicity.

    BLOOD TREATMENT
    8.
    发明专利
    BLOOD TREATMENT 失效

    公开(公告)号：JPS63203623A

    公开(公告)日：1988-08-23

    申请号：JP3574087

    申请日：1987-02-20

    Applicant: TORAY INDUSTRIES

    Inventor： MAEBUCHI ETSUKO ,  TERAMOTO KAZUO ,  KODAMA MASATOMO ,  TANI TORU ,  ENDO YOSHIHIRO

    IPC: A61K31/715 ,  A61K35/74 ,  A61M1/36 ,  A61P35/00

    Abstract: PURPOSE:To obtain a blood treatment having excellent antitumor action, by immobilizing a lipopolysaccharide derived from Gram-negative bacterium cell wall, having reduced toxicity by deacylation, to an insoluble carrier. CONSTITUTION:Fatty acid ester groups are partially or totally removed from lipopolysaccharides partially existing in the outer layer of cell wall of Gram-negative bacteria by the use of hydroxylamine, etc., and the lipopolysaccharides are deacylated. Then the lipoposaccharides are bonded to an insoluble carrier (e.g. carrier comprising a vinyl polymer as a main polymer) or further the mixture is blended with a condensation agent for peptide synthesis, such as dicyclohexylcarbodiimide, etc., to give the aimed substance. The density of deacylated lipopolysaccharide in the immobilized deacylated lipopolysaccharide is >=0.01mg/g, preferably >=1.0mg/g.

Patent Agency Ranking